Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04905121

Organisation Name: Beckley Psytech Limited

Overal Status: Recruiting

Start Date: July 15, 2021

Last Update: July 14, 2021

Lead Sponsor: Beckley Psytech Limited

Brief Summary: This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Conditions:
  • Short Lasting Unilateral Neuralgiform Headache Attacks


Total execution time in seconds: 0.29635500907898